文献速递外周动脉疾病

外周动脉疾病血运重建后VascuQoL-6的最小重要差异与显著临床获益评估

Assessment of Minimum Important Difference and Substantial Clinical Benefit with the Vascular Quality of Life Questionnaire-6 when Evaluating Revascularisation Procedures in Peripheral Arterial Disease.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2017-07-25

基于瑞典血管 registry 的观察性队列研究,纳入3194例外周动脉疾病血运重建患者,采用分布法与锚定法确定VQ-6最小重要差异,并用ROC曲线确定显著临床获益阈值。间歇性跛行患者1年最小重要差异为1.7–2.2个量表步,显著临床获益阈值为3.5步;严重肢体缺血患者分别为1.9步和4.5步,ROC判别能力在跛行组优秀(AUC 0.87)、缺血组可接受(AUC 0.736)。

要点

  • 间歇性跛行患者VQ-6最小重要差异为1.7–2.2个量表步,显著临床获益阈值为3.5步。
  • 严重肢体缺血患者VQ-6最小重要差异为1.9个量表步,显著临床获益阈值为4.5步。
  • VQ-6判别显著临床获益的AUC在跛行组为0.87,缺血组为0.736。

核心结论

  • 建议的VQ-6最小重要差异和显著临床获益阈值可用于评估外周动脉疾病不同干预后的结局及临床试验设计。

研究设计与样本

  • 基于人群的观察性队列研究,分析瑞典血管 registry 2014年1月至2016年9月血运重建的外周动脉疾病患者。
  • 共纳入3194例有完整VQ-6基线记录的患者,其中间歇性跛行1622例,严重肢体缺血1572例。
  • 2996例有术后30天完整VQ-6记录,1092例有术后1年完整记录。

主要发现

  • 间歇性跛行患者血运重建后1年最小重要差异范围为1.7至2.2个量表步,取决于分析方法。
  • 严重肢体缺血患者1年最小重要差异为1.9个量表步。
  • ROC分析显示VQ-6判别显著临床获益的能力在间歇性跛行患者优秀(AUC 0.87,敏感性0.81,特异性0.76),在严重肢体缺血患者可接受(AUC 0.736,敏感性0.63,特异性0.72)。

关键数值与推荐

  • 间歇性跛行患者显著临床获益的VQ-6最佳阈值为3.5个量表步。
  • 严重肢体缺血患者显著临床获益的VQ-6最佳阈值为4.5个量表步。

临床怎么用

  • 临床评估外周动脉疾病血运重建后生活质量改善时,可采用VQ-6最小重要差异和显著临床获益阈值解读变化。
  • 在临床试验设计中,可使用上述阈值定义有临床意义的结局指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Patient reported outcomes are increasingly used to assess outcomes after peripheral arterial disease (PAD) interventions. VascuQoL-6 (VQ-6) is a PAD specific health-related quality of life (HRQoL) instrument for routine clinical practice and clinical research. This study assessed the minimum important difference for the VQ-6 and determined thresholds for the minimum important difference and substantial clinical benefit following PAD revascularisation. MATERIALS AND METHODS: This was a population-based observational cohort study. VQ-6 data from the Swedvasc Registry (January 2014 to September 2016) was analysed for revascularised PAD patients. The minimum important difference was determined using a combination of a distribution based and an anchor-based method, while receiver operating characteristic curve analysis (ROC) was used to determine optimal thresholds for a substantial clinical benefit following revascularisation. RESULTS: A total of 3194 revascularised PAD patients with complete VQ-6 baseline recordings (intermittent claudication (IC) n = 1622 and critical limb ischaemia (CLI) n = 1572) were studied, of which 2996 had complete VQ-6 recordings 30 days and 1092 a year after the vascular intervention. The minimum important difference 1 year after revascularisation for IC patients ranged from 1.7 to 2.2 scale steps, depending on the method of analysis. Among CLI patients, the minimum important difference after 1 year was 1.9 scale steps. ROC analyses demonstrated that the VQ-6 discriminative properties for a substantial clinical benefit was excellent for IC patients (area under curve (AUC) 0.87, sensitivity 0.81, specificity 0.76) and acceptable in CLI (AUC 0.736, sensitivity 0.63, specificity 0.72). An optimal VQ-6 threshold for a substantial clinical benefit was determined at 3.5 scale steps among IC patients and 4.5 in CLI patients. CONCLUSIONS: The suggested thresholds for minimum important difference and substantial clinical benefit could be used when evaluating VQ-6 outcomes following different interventions in PAD and in the design of clinical trials.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Nordanstig J, Pettersson M, Morgan M, et al. Assessment of Minimum Important Difference and Substantial Clinical Benefit with the Vascular Quality of Life Questionnaire-6 when Evaluating Revascularisation Procedures in Peripheral Arterial Disease. Eur J Vasc Endovasc Surg. 2017. PMID: 28754429. doi:10.1016/j.ejvs.2017.06.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。